GSK Dodges Securities Fraud Class Action Over Zantac Deception

Drugmaker GSK PLC won’t have to answer a securities fraud class action stemming from its concealment of a link between Zantac and a cancer-causing substance because it was filed too late.

Widely publicized allegations and news articles reporting on Zantac’s use of a carcinogen-containing active ingredient should have led reasonably diligent class members to have discovered the events giving rise to their claims more than two years before filing suit, the US District Court for the Eastern District of Pennsylvania said Wednesday. The delay rendered the filing untimely, Judge Chad F. Kenney said in dismissing the suit.

The popular over-the-counter ...